Tratamiento anticoagulante prolongado con rivaroxabán para la embolia pulmonar de bajo riesgo asociada a cáncer según diferentes puntuaciones del estado funcional: aportaciones del ensayo aleatorizado ONCO PE

BACKGROUND: The ONCO PE (Optimal Duration of Anticoagulation Therapy for Low-Risk Pulmonary Embolism Patients With Cancer) trial demonstrated the superiority of 18-month compared with 6-month rivaroxaban treatment for cancer-associated low-risk pulmonary embolism in reducing recurrent venous thromboembolism. However, it was uncertain whether the results could be applicable to patients with different performance status (PS) scores, which evaluate the physical condition of patients with cancer undergoing anticancer treatment. METHODS: In this post hoc subgroup analysis of the ONCO PE trial, we compared the 18-month and 6-month rivaroxaban treatment groups in 2 subgroups: the low PS score (no restricted physical activity: PS=0; n=79) and high PS score (restricted physical activity: PS ≥1; n=99) subgroups. The primary end point was recurrent venous thromboembolism, and the major secondary end point was major bleeding. RESULTS: The rate of recurrent venous thromboembolism was lower in the 18-month rivaroxaban group than in the 6-month rivaroxaban group, significantly among the low PS score subgroup (2.7% versus 19.0%, P=0.049) and numerically among the high PS score subgroup without statistical significance (7.7% versus 19.1%, P=0.10). The rate of major bleeding was not different between the 2 groups among the low PS score subgroup (2.7% versus 7.1%, P=0.39), while it was numerically higher in the 18-month rivaroxaban group than in the 6-month rivaroxaban group among the high PS score subgroup, without statistical significance (11.5% versus 4.3%, P=0.20). CONCLUSIONS: Extended anticoagulation therapy for patients with cancer-associated low-risk pulmonary embolism might have a potential benefit in reducing thrombotic risk irrespective of PS score, whereas there might be some concerns on an increased risk of major bleeding in patients with a high PS score. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique Identifier: NCT04724460.

Resumen tomado de PubMed (NCBI) para el registro citado, en el idioma original. La versión de referencia es la de la publicación original.

El resumen se deja sin traducir para conservar la redacción original de los autores.

Subanálisis post hoc del ensayo ONCO PE (rivaroxabán 18 vs. 6 meses en embolia pulmonar de bajo riesgo asociada al cáncer) por estado funcional: PS=0, n=79; PS≥1, n=99. La tromboembolia venosa recurrente fue menor con 18 meses: significativa con PS=0 (2,7 % vs. 19,0 %; p = 0,049) y numérica con PS≥1. La hemorragia mayor no difirió significativamente; con PS≥1 fue numéricamente mayor. Los autores ven posible beneficio con cualquier PS y cierta preocupación por sangrado con PS alto.

Explore cómo esta investigación se conecta con la práctica clínica

Más estudios revisados por pares en la categoría «Seguridad y control de infecciones».

• Leech-Assisted Flap Salvage — Systematic Review of 277 Cases — Whitaker et al. (2012)
• Effects of hirudotherapy on liver functions, lipid profile, and insulin sensitivity in rats with metabolic syndrome — Bilden A et al. (2026)
• Efficacy and Safety of Hirudotherapy for Improving Sperm Quality Parameters in Male Infertility: A Randomized Controlled Trial — Abtahi-Forooshani M et al. (2026)
• Improvement of patient care through hirudotherapy and the management of leeches from their reception to their disposal in France — Vaesken C et al. (2023)
• Hirudotherapy in Medicine and Dentistry — Jha K et al. (2015)
• Management of Chronic Non-healing Wounds by Hirudotherapy — Iqbal A et al. (2017)
• La hirudoterapia atenúa el dolor artrítico en pacientes con diversos síndromes de dolor crónico: un análisis retrospectivo — Loeser J et al. (2020)
• Hirudotherapy (medicinal leeches) for treatment of upper airway obstruction in a dog — Trenholme H, Masseau I, Reinero C (2021)
• Análisis de infecciones resistentes a antibióticos asociadas a la hirudoterapia — Brauer P et al. (2024)
• ¡Déjame en paz, sanguijuela! Hemartrosis atraumática tras hirudoterapia — Curcio J, Lloyd C (2020)

Ver toda la investigación analizada por la ASH →